Open-Label Study With Pimavanserin on Activities of Daily Living in Subjects With Parkinson's Disease Psychosis

PHASE4CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

February 10, 2020

Primary Completion Date

April 26, 2022

Study Completion Date

April 26, 2022

Conditions
Parkinson Disease Psychosis
Interventions
DRUG

Pimavanserin

Pimavanserin 34 mg (provided as 1×34 mg capsule), administered orally, once daily for 16 weeks

Trial Locations (18)

30912

AU Movement and Memory Disorders, Augusta

32127

Accel Research Sites - Brain and Spine Institute, Port Orange

33016

Global Health Research Center, Inc., Miami Lakes

33064

Quantum Laboratories, Inc., Pompano Beach

33122

Premier Clinical Research Institute, Inc., Miami

33351

Infinity Clinical Research, LLC, Sunrise

33407

Premiere Research Institute at Palm Beach Neurology, West Palm Beach

33980

Parkinson's Disease Treatment Center of Southwest Florida, Port Charlotte

37067

KCA Neurology, Franklin

43054

The Orthopedic Foundation, New Albany

45459

Neurology Diagnostics, Inc., Dayton

74136

Central States Research, Tulsa

75218

Neurological Associates of North Texas, Dallas

85258

Movement Disorders Center of Arizona, Scottsdale

92835

Neurology Center of North Orange County, Fullerton

04074

Maine Medical Partners Neurology, Scarborough

03820

Wentworth Health Partners Coastal Neurology Services, Dover

08755

Bio Behavioral Health, Toms River

Sponsors
All Listed Sponsors
lead

ACADIA Pharmaceuticals Inc.

INDUSTRY